Tag: PARP inhibitors

Medical Topics

Triple-Negative Breast Cancer: Modern Treatment Strategies and Latest Clinical Trials

Triple-negative breast cancer (TNBC) is an aggressive subtype with limited treatment options. In 2025, immunotherapy, PARP inhibitors, and antibody-drug conjugates are transforming care. New protocols reduce toxicity while improving outcomes, and personalized vaccines are showing promise in early trials.